[Penetration of imipenem/cilastatin sodium into the tissues of the female reproductive organs].
A new combined preparation, imipenem/cilastatin (MK-0787/MK-0791), was evaluated its penetration into the plasma and tissues with the following results: After an intravenous drip infusion of 500 mg/500 mg of MK-0787/MK-0791, the plasma concentration of drug achieved in the uterine artery was almost equal to that in the antecubital vein, showing good penetration of the drug. After an intravenous drip infusion of 500 mg/500 mg of MK-0787/MK-0791, favorable concentrations were achieved in all of the adnexal and uterine tissues studied. From the results obtained, it is expected that MK-0787/MK-0791 will be highly effective in the field of obstetrics and gynecology.
Maeda
Y
Y
Sengoku
K
K
Mure
K
K
Yamashita
K
K
Shimizu
T
T
D000290:Adnexa Uteri / Q000378:metabolism*; D000328:Adult; D000368:Aged; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000097:blood; D004338:Drug Combinations; D005260:Female; D006801:Humans; D015378:Imipenem; D007262:Infusions, Intravenous; D008875:Middle Aged; D013845:Thienamycins / Q000008:administration & dosage* / Q000097:blood; D014599:Uterus / Q000098:blood supply / Q000378:metabolism*
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem